Regeneron’s coronavirus antibody cocktail therapy against COVID-19, famously used to treat president Donald Trump, has hit a safety issue after independent safety experts recommended it sho
COVID-19 vaccines could be approved and available early next year in the UK ahead of other European countries, after its national regulator began its own rolling reviews of shots from Astra
Gilead’s Veklury (remdesivir) has failed to produce an effect on hospital stay and mortality in COVID-19 patients in a large global trial, casting doubt on previous supportive study finding
An antibody cocktail from Regeneron has been approved by the FDA as the first treatment for Ebola, offering hope that a similar approach could be used to combat COVID-19.
There is growing evidence that the coronavirus may be able to re-infect patients, and a new instance of a second infection has been confirmed in the US.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
